PBAC July Meeting Agenda Summary for rare and less common cancers
- Acalabrutinib (Calquence). Chronica long-lasting disease that changes slowly over time lymphocytic leukaemiacancer of blood and/or blood forming tissues (CLL) or small lymphocytic lymphomacancers of the lymphatic system (SLL). For the treatment of patients (either as monotherapy or in combination with obinutuzumab) with previously untreated CLL or SLL considered unsuitable for treatment with a purine analogue.
- Atezolizumab (Tecentriq) + Bevacizumab (Avastin). Hepatocellular carcinomacancer arising from tissues that line organs. For the treatment of patients with advancedat a late stage, far along (unresectable) locally advanced or metastatic Liver Cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs Stage B or Stage C HCC who have not received prior systemic therapy.
- Mogamulizumab (Poteligeo). Cutaneous T-Cell Lymphoma (CTCL). For patients with relapsed or refractory CTCL who have been previously treated with at least one prior systemic therapy.
- Nivolumab (Opdivo) + Ipilumumab (Yervoy). Non-small Cell Lung cancer (NSCLC)
For nivolumab and ipilimumab to include the first-line treatment of patients with stage IV NSCLC.
- Olaparib (Lynparza). Ovarian, fallopian tube or primary peritoneal cancer. For newly diagnosed advanced BRCA-mutated high gradea description of how abnormal cancer cells and tissue look under a microscope when compared to healthy cells epithelial ovarian, fallopian tube or primary peritoneal cancer in response (complete or partial) to first-line platinum-based chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells.
- Osimertinib (Tagrisso). Non-small cell lung cancer (NSCLC). For the first line treatment of patients with Stage IIIB (locally advanced) or Stage IV (metastatic), epidermal growth factor receptor (EGFR) mutation positive NSCLC.